Source comparison
Ipamorelin for Recovery: Research Methods Comparison
The following table summarizes key research approaches evaluating ipamorelin for recovery across different tissue types and injury models. Understanding study design helps contextualize findings and identify which applications have the strongest evidence base.
This comparison does not assign a generated winner or score.
- The following table summarizes key research approaches evaluating ipamorelin for recovery across different tissue types and injury models. Understanding study design helps contextualize findings and identify which applications have the strongest evidence base.
- Rodent tendon injury
- 100–200 mcg/kg daily SC
- Tensile strength, collagen type I/III ratio, histological inflammation score
- 14–28 days
- Controlled studies with biomechanical validation. Strongest preclinical evidence
- Human chronic wound healing
- 200–300 mcg twice daily SC
- Wound surface area reduction, time to epithelialization, infection rates
- 8–12 weeks
- Small pilot studies (n=12–24). Preliminary human data, limited statistical power
- Post-surgical orthopedic recovery
- 250 mcg nightly SC
- Time to weight-bearing, functional scores (IKDC, Lysholm), quadriceps strength
- 12–16 weeks
- Case series and single-center trials. Hypothesis-generating but not definitive
- Athletic overuse injury
- 200 mcg pre-sleep SC
- Ultrasound tissue characteristics, pain scores (VAS), return-to-play timeline
- 6–12 weeks
- Observational cohorts without controls. Weakest evidence tier but most clinically relevant population
- Bone fracture healing
- 150 mcg/kg daily SC (animal)
- Radiographic callus formation, mineral density (DEXA), biomechanical testing
- 6–8 weeks
- Animal models only. No completed human RCTs as of 2026
- This comparison reveals that ipamorelin for recovery has the strongest evidence base in soft tissue applications (tendons, wounds) and weakest in bone healing and muscle hypertrophy. The gap between animal models and human clinical trials remains substantial. Most human data comes from small pilot studies rather than adequately powered randomized controlled trials.